These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1017110)

  • 1. Molecular orbital index-activity relationship between atrial antiarrhythmic activity and disopyramide derivatives.
    Lin TK; Chien YW; Desai HB; Yonan PK
    Chem Pharm Bull (Tokyo); 1976 Nov; 24(11):2739-43. PubMed ID: 1017110
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
    Bernhart CA; Condamine C; Demarne H; Roncucci R; Gagnol JP; Gautier PJ; Serre MA
    J Med Chem; 1983 Mar; 26(3):451-5. PubMed ID: 6827566
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantum statistical calculation for the correlation of biological activity and chemical structure. 3. Diisopyramide phosphate and related compounds as antiarrhythmic agents.
    Lin TK; Chien YW; Dean RR; Dutt JE; Sause HW; Yen CH; Yonan PK
    J Med Chem; 1974 Jul; 17(7):751-3. PubMed ID: 4836408
    [No Abstract]   [Full Text] [Related]  

  • 4. Linear relationships between plasma binding and lipophilicity of disopyramide derivatives.
    Chien YW; Lambert HJ; Lin TK
    J Pharm Sci; 1975 Jun; 64(6):961-6. PubMed ID: 1133751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compounds related to 4-disopropylamino-2-phenyl-2(2-pyridyl)butyramide. Their synthesis and antiarrhythmic activity.
    Yen CH; Lowrie HS; Dean RR
    J Med Chem; 1974 Nov; 17(11):1131-5. PubMed ID: 4412561
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of pKb on lipophilic binding of disopyramide derivatives to human plasma.
    Chien YW; Akers MJ; Yonan PK
    J Pharm Sci; 1975 Oct; 64(10):1632-5. PubMed ID: 241827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide plasma and myocardial tissue concentrations as they relate to antiarrhythmic activity.
    Patterson E; Stetson P; Lucchesi BR
    J Cardiovasc Pharmacol; 1979; 1(5):541-50. PubMed ID: 94410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
    Inoue H; Yamashita T; Usui M; Nozaki A; Sugimoto T
    Cardiovasc Res; 1991 Mar; 25(3):223-9. PubMed ID: 1903082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antidysrhythmic profiles of bepridil, amiodarone and disopyramide in the guinea-pig and dog.
    Labrid C; Leinot M; Beaughard M; Basiez M; Duchene-Marullaz P
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):87-97. PubMed ID: 6971633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of disopyramide and its mono-N-dealkylated metabolite in conscious dogs with chronic atrioventricular block: plasma concentration-response relationships.
    Dubray C; Boucher M; Paire M; Pinatel H; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1986; 8(6):1229-34. PubMed ID: 2434751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.
    Grant AM; Marshall RJ; Ankier SI
    Eur J Pharmacol; 1978 Jun; 49(4):389-94. PubMed ID: 668810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic effect of disopyramide injected into the sinus nodal artery.
    Garcia-Barreto D; Pérez-Medina T
    Acta Physiol Acad Sci Hung; 1977; 49(3-4):231-5. PubMed ID: 755338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate.
    Mathur PP
    Am Heart J; 1972 Dec; 84(6):764-70. PubMed ID: 4150336
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologically active conformation of disopyramide: evidence from apparent pKa measurements.
    Czeisler JL; el-Rashidy RM
    J Pharm Sci; 1985 Jul; 74(7):750-4. PubMed ID: 4032248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of disopyramide (Norpace): toxic interactions with other antiarrhythmic agents.
    Ellrodt G; Singh BN
    Heart Lung; 1980; 9(3):469-74. PubMed ID: 6901519
    [No Abstract]   [Full Text] [Related]  

  • 16. Some pharmacological effects of disopyramide and a metabolite.
    Baines MW; Davies JE; Kellett DN; Munt PL
    J Int Med Res; 1976; 4(1 Suppl):5-7. PubMed ID: 193744
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative comparison of the anticholinergic and antiarrhytmic actions of disopyramide and quinidine.
    Pérez A; Ledea N; Hermández K; Garcia-Barreto D
    Pol J Pharmacol Pharm; 1977; 29(5):527-32. PubMed ID: 593967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of class I antiarrhythmic agents, disopyramide, pirmenol, and pentisomide for peripheral muscarinic M2 and M3 receptors.
    Endou M; Hattori Y; Gando S; Kanno M
    J Cardiovasc Pharmacol; 1992 May; 19(5):674-81. PubMed ID: 1381764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of atropine, propafenon and disopyramide on "sino-atrial conduction time" in man].
    Breithardt G; Seipel L; Both A; Loogen F
    Verh Dtsch Ges Inn Med; 1975; 81():1634-7. PubMed ID: 1227042
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.